In order to obtain a cross-entity assessment that is not only focused on AML and to obtain an initial overview of the effects of the polymorphism, we addressed this question in the human myeloid leukemia cell line K562, in which we knocked in a GFI1-36N variant. The gene discussed is GFI1; the disease is myeloid leukemia.